A computer based survey program, BioWindows(TM) is designed for individuals to compile personalized in-depth profiles to help determine the most appropriate medical solution. Each individual confidentially enters personal information, including demographics, medical history, and lifestyle choices, into a database. This survey, in combination with a specific tissue biopsy, allows for medical professionals to accurately assess the most optimal form of treatment. The database facilitates comparisons with a central repository of gene profiles to assist doctors and scientists in using targeted diagnostic to personalize medical treatments.

"The launch of our informatics system, BioWindows(TM), is paving the way for Iris's debut in the public marketplace," says Simon Chin, founder, chairman, and chief executive officer of Iris BioTechnologies. "It signifies a critical step for Iris as it evidences our team's hard work and commitment to the company's mission and to the field of personalized medicine."

Iris BioTechnologies is dedicated to identifying gene expression patterns. By profiling genomic information using their patented Nano-BioChip(TM) and analyzing these patterns and important factors contained in the interactive BioWindows survey, Iris has designed a remarkably comprehensive personalized medicine platform.

"Our BioWindows(TM) platform, coupled with our proprietary Nano-BioChip(TM), will soon help to identify effective methods to optimize breast cancer treatment, reduce both disease risk and medical costs while ultimately improving the patient quality of life," Chin continues. "The information garnered by our database will not only help patients and their families, but those in generations to follow. There is currently a void in our medical system when it comes to targeted, individualized treatment, and we believe we have the solution."

Iris BioTechnologies (www.irisbiotech.com), located in Santa Clara, CA, is a theranostics company, dedicated to creating a novel approach to monitor gene expression levels and mutations in order to identify the ideal treatment solution for patients. By categorizing individuals according to their genomic and personal profiles, Iris BioTechnologies accurately determines the optimal medical solution for each patient through a proprietary informatics program, BioWindows. Iris's ever expanding database, in addition to their developments of the Comprehensive Cancer Chip(TM), NeuroChip(TM), CardioChip(TM), and MetabolicChip(TM) adds to their extensive product pipeline. The company's first biochip, the BreastCancerChip, is expected to be available in the second half of 2008.

For further information, visit the company website at www.irisbiotech.com.

This is cache, read story here

Posted in login to post comments